|Articles|December 4, 2015
Bio-Optronics Renews Its Global Impact Partnership with the Society for Clinical Research Sites
Advertisement
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced the renewal of a two-year relationship with Bio-Optronics, a leading healthcare information technology company, focusing specifically on workflow optimization. Bio-Optronics will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
Christine Pierre, president of SCRS, said, “We are thrilled to have Bio-Optronics continue to show their support of the sites through their collaboration with SCRS as a Global Impact Partner. We welcome the opportunity for further collaboration between the two organizations.”
“SCRS continues to serve as a the most prominent resource for the research site community to thrive and collectively grow, and we are eager to continue this partnership, serve as a resource to the site community and continue to grow Clinical Conductor CTMS to further accommodate the needs of research sites,” stated Maria Durkin, Chief Business Officer of Bio-Optronics.
As a Global Impact Partner (GIP), Bio-Optronics will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
3
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
4
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
5